OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
06 August 2024 - 9:00PM
UK Regulatory
OKYO Pharma Granted European Patent Covering OK-101 Chemerin
Analogs and Their Method of Use
LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO
Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical
company developing innovative ocular therapies for the treatment of
inflammatory dry eye disease (DED), a multi-billion-dollar market,
and anterior ocular segment diseases including neuropathic corneal
pain (NCP), an ocular condition associated with pain but without an
FDA approved therapy, announced today the grant of a key
European Patent entitled: “Compositions Comprising Chemerin Analogs
and Methods of Use”. The present disclosure that lists Raj Patil,
Chief Scientific Officer of OKYO Pharma as a joint Inventor,
relates to novel OK-101 chemerin analogs for use in treating
various diseases and conditions including but not limited to,
ocular inflammatory and pain conditions, strengthening the
Company’s intellectual property position in this field.
"We are delighted with the issuance of this European patent,
which underscores the innovative nature of our OK-101 chemerin
analogs and their therapeutic potential. This milestone strengthens
our intellectual property portfolio and positions OKYO Pharma for
continued advancement in addressing significant unmet medical
needs," commented Dr. Gary S. Jacob, Ph.D., CEO of OKYO. “The
issuance of this patent further solidifies OKYO Pharma's commitment
to advancing novel therapies that aim to improve outcomes for
patients suffering from ocular pain and inflammation. The company
continues to explore strategic partnerships and collaborations to
accelerate the development and commercialization of its pipeline
candidates.”
About OK-101
OK-101 is a lipid conjugated chemerin peptide agonist of the
ChemR23 G-protein coupled receptor which is typically found on
immune cells of the eye responsible for the inflammatory response.
OK-101 was developed using a membrane-anchored-peptide technology
to produce a novel long-acting drug candidate for treating dry eye
disease. OK-101 has been shown to produce anti-inflammatory and
pain-reducing efficacy signals in mouse models of dry eye disease
and corneal neuropathic pain (NCP), respectively, and is designed
to combat washout through the inclusion of the lipid anchor built
into the drug molecule to enhance the residence time of OK-101
within the ocular environment. OK-101 recently showed statistical
significance in multiple endpoints in a recently completed Phase 2,
multi-center, double-blind, placebo-controlled trial of OK-101 to
treat DED.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage
biopharmaceutical company developing innovative therapies for the
treatment of DED and NCP, with ordinary shares listed for trading
on the NASDAQ Capital Market. OKYO is focused on the discovery and
development of novel molecules to treat inflammatory DED and ocular
pain. In addition to the recently completed Phase 2 DED trial, OKYO
also has plans underway for the opening of a Phase 2 trial for
OK-101 to treat NCP in patients with this debilitating condition.
For further information, please visit www.okyopharma.com.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company’s current expectations,
estimates, and projections about its industry, its beliefs, and
assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’
‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company’s control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
These and additional risks and uncertainties are described more
fully in the company’s filings with the SEC, including those
factors identified as “Risk Factors” in our most recent Annual
Report on Form 20-F, for the fiscal year ended March 31,
2023. The Company cautions security holders and prospective
security holders not to place undue reliance on these
forward-looking statements, which reflect the view of the Company
only as of the date of this announcement. The forward-looking
statements made in this announcement relate only to events as of
the date on which the statements are made. The Company will not
undertake any obligation to release publicly any revisions or
updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
Enquiries:
OKYO Pharma Limited
|
Gary S. Jacob, Chief Executive Officer |
917-497-7560 |
Business Development
&
Investor Relations |
Paul Spencer |
+44 (0)20 7495 2379
|
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Sep 2023 to Sep 2024